10084-TB-2 IN VITRO CHARACTERIZATION OF COMBINATION THERAPY IN GENETICALLY-ENGINEERED MURINE DIFFUSE MIDLINE GLIOMA MODELS
Yusuke Tomita, Nozomu Takata, Oren Becher · 2023
Read 10084-TB-2 IN VITRO CHARACTERIZATION OF COMBINATION THERAPY IN GENETICALLY-ENGINEERED MURINE DIFFUSE MIDLINE GLIOMA MODELS by Yusuke Tomita, Nozomu Takata, Oren Becher (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10710603.txt.
Description
Diffuse midline glioma is a childhood brain cancer with no approved drug that extends life. Yusuke Tomita, Nozomu Takata, and Oren Becher built a mouse version of the disease in 2023. They switched on a growth signal, added the H3.3K27M mutation, and deleted the p53 gene in brainstem progenitor cells. The mice developed brainstem gliomas and lived a median of about 62 days.
From the tumor tissue the team grew a cell line in spheroid culture that kept the cancer's growth and invasive behavior; placed against a hindbrain organoid, the cells invaded it. Two drug classes suggested by molecular studies, a CDK4/6 blocker and a MEK blocker, were tested together. The pair showed a mild joint benefit in killing cells and triggering cell death. The authors offer the cell line as a tool for further drug testing against this cancer.
Catalog record
| CREATOR | Yusuke Tomita, Nozomu Takata, Oren Becher |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |